Corpus ID: 40141364

Technology evaluation: ISIS-104838, OraSense.

@article{Kennewell2003TechnologyEI,
  title={Technology evaluation: ISIS-104838, OraSense.},
  author={P. Kennewell},
  journal={Current opinion in molecular therapeutics},
  year={2003},
  volume={5 1},
  pages={
          76-80
        }
}
  • P. Kennewell
  • Published 2003
  • Medicine, Biology
  • Current opinion in molecular therapeutics
  • OraSense Ltd (a joint venture between Isis Pharmaceuticals Inc and Elan Corp) is developing ISIS-104838, an antisense oligonucleotide specific for TNF alpha mRNA, as an inhibitor of TNF alpha synthesis. The compound is being developed for the potential treatment of inflammatory diseases such as rheumatoid arthritis, Crohn's disease and psoriasis. This antisense oligonucleotide is currently undergoing phase II clinical trials for RA and Crohn's disease. 
    10 Citations

    Topics from this paper.

    Molecular therapeutic targets in rheumatoid arthritis.
    • 76
    Gene Therapy for Rheumatoid Arthritis
    • 8
    MOLECULAR TARGET AND THERAPEUTIC ASPECTS OF RHEUMATOID ARTHRITIS: A REVIEW
    • 2
    T cell targeted immunotherapy for autoimmune disease
    • 6
    Advances in Antisense Oligonucleotide Development for Target Identification, Validation, and as Novel Therapeutics
    • 45
    • PDF
    Peroxide-mediated desulfurization of phosphorothioate oligonucleotides and its prevention.
    • 15
    2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents.
    • M. Koizumi
    • Biology, Medicine
    • Biological & pharmaceutical bulletin
    • 2004
    • 11
    • PDF
    Sulfur-centered hemi-bond radicals as active intermediates in S-DNA phosphorothioate oxidation